Literature DB >> 25542737

Total and differential white blood cell counts, high-sensitivity C-reactive protein, and cardiovascular risk in non-affective psychoses.

Brian J Miller1, Prianka Kandhal2, Mark Hyman Rapaport3, Andrew Mellor4, Peter Buckley2.   

Abstract

Schizophrenia is associated with increased cardiovascular disease morbidity and mortality. Schizophrenia is also associated with immune and inflammatory abnormalities, including aberrant blood levels of lymphocytes, cytokines and high-sensitivity C-reactive protein (hsCRP). The purpose of this study is to investigate the relationship between total and differential white blood cell (WBC) counts, hsCRP, and indices of cardiovascular disease risk in patients with schizophrenia and related non-affective psychoses. 108 inpatients and outpatients age 18-70 with non-affective psychoses and 44 controls participated in this cross-sectional study. Subjects had a fasting blood draw between 8 and 9am for glucose, lipids, total and differential WBC counts, and hsCRP. Vital signs and medical history were obtained. Patients with non-affective psychosis had significantly higher hsCRP levels than controls (p=0.04). In linear regression analyses, lymphocyte and monocyte counts were a significant predictor of the total-to-HDL cholesterol ratio in subjects with non-affective psychosis (p⩽0.02 for each). In binary logistic regression analyses, total WBC count was a significant predictor of an elevated 10-year estimated risk of myocardial infarction and cardiovascular disease in subjects with non-affective psychosis (p⩽0.03 for each). Associations between total and differential WBC counts and cardiovascular disease risk indices were stronger in males than females with non-affective psychosis. Our findings provide further evidence that measurement of total and differential WBC counts may be germane to the clinical care of patients with schizophrenia and related disorders, and support an association between inflammation and cardiovascular disease risk in these patients.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  C-reactive protein; Cardiovascular disease; Inflammation; Leukocytes; Lymphocytes; Monocytes; Neutrophils; Non-affective psychosis; Risk assessment; Schizophrenia

Mesh:

Substances:

Year:  2014        PMID: 25542737      PMCID: PMC4286154          DOI: 10.1016/j.bbi.2014.12.005

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  44 in total

1.  Haemorheological, platelet and endothelial indices in relation to global measures of cardiovascular risk in hypertensive patients: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial.

Authors:  C G C Spencer; D C Felmeden; A D Blann; G Y H Lip
Journal:  J Intern Med       Date:  2007-01       Impact factor: 8.989

2.  Increased Framingham 10-year risk of coronary heart disease in middle-aged and older patients with psychotic symptoms.

Authors:  Hua Jin; David Folsom; Alana Sasaki; Sunder Mudaliar; Robert Henry; Monique Torres; Shah Golshan; Danielle K Glorioso; Dilip Jeste
Journal:  Schizophr Res       Date:  2010-11-19       Impact factor: 4.939

Review 3.  What does minor elevation of C-reactive protein signify?

Authors:  Irving Kushner; Debra Rzewnicki; David Samols
Journal:  Am J Med       Date:  2006-02       Impact factor: 4.965

4.  The prevalence and clinical correlates of metabolic syndrome in patients with schizophrenia: findings from a cohort in Turkey.

Authors:  M K Yazici; A E Anil Yağcioğlu; A Ertuğrul; N Eni; S Karahan; E Karaağaoğlu; S L Tokgözoğlu
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-06-03       Impact factor: 5.270

5.  The relationship between serum brain-derived neurotrophic factor (BDNF) and cardiometabolic indices in schizophrenia.

Authors:  Milawaty Nurjono; Yi Hang Tay; Jimmy Lee
Journal:  Schizophr Res       Date:  2014-06-14       Impact factor: 4.939

Review 6.  Role of C-reactive protein in contributing to increased cardiovascular risk in metabolic syndrome.

Authors:  Sridevi Devaraj; Simona Valleggi; David Siegel; Ishwarlal Jialal
Journal:  Curr Atheroscler Rep       Date:  2010-03       Impact factor: 5.113

7.  Best-estimate versus structured interview-based diagnosis in first-admission psychosis.

Authors:  S Fennig; T Craig; J Lavelle; B Kovasznay; E J Bromet
Journal:  Compr Psychiatry       Date:  1994 Sep-Oct       Impact factor: 3.735

Review 8.  Chlorpromazine equivalent doses for the newer atypical antipsychotics.

Authors:  Scott W Woods
Journal:  J Clin Psychiatry       Date:  2003-06       Impact factor: 4.384

9.  Metabolic syndrome and cardiovascular risk among patients with schizophrenia receiving antipsychotics in Malaysia.

Authors:  Mas Ayu Said; Ahmad Hatim Sulaiman; Mohd Hussain Habil; Srijit Das; Abdul Kadir Abu Bakar; Rosliwati Md Yusoff; Tsui Huei Loo; Shamshunnisah Abu Bakar
Journal:  Singapore Med J       Date:  2012-12       Impact factor: 1.858

10.  Clinical phenotypes of psychosis in the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP).

Authors:  Carol A Tamminga; Elena I Ivleva; Matcheri S Keshavan; Godfrey D Pearlson; Brett A Clementz; Bradley Witte; David W Morris; Jeffrey Bishop; Gunvant K Thaker; John A Sweeney
Journal:  Am J Psychiatry       Date:  2013-11       Impact factor: 18.112

View more
  7 in total

1.  Parental type 2 diabetes in patients with non-affective psychosis.

Authors:  Brian J Miller; David R Goldsmith; Nina Paletta; Joyce Wong; Prianka Kandhal; Carmen Black; Mark Hyman Rapaport; Peter F Buckley
Journal:  Schizophr Res       Date:  2016-05-04       Impact factor: 4.939

2.  Inflammation as a unique marker of suicide ideation distinct from depression syndrome among U.S. adults.

Authors:  Rachel S Bergmans; Kristen M Kelly; Briana Mezuk
Journal:  J Affect Disord       Date:  2018-11-06       Impact factor: 4.839

3.  Associations of high sensitivity C-reactive protein levels in schizophrenia and comparison groups.

Authors:  Jamie Joseph; Colin Depp; Averria Sirkin Martin; Rebecca E Daly; Danielle K Glorioso; Barton W Palmer; Dilip V Jeste
Journal:  Schizophr Res       Date:  2015-09-02       Impact factor: 4.939

Review 4.  First-episode psychosis: How long does it last? A review of evolution and trajectory.

Authors:  Jyoti Prakash; K Chatterjee; K Srivastava; V S Chauhan
Journal:  Ind Psychiatry J       Date:  2021-07-20

Review 5.  Is It Possible to Predict the Future in First-Episode Psychosis?

Authors:  Jaana Suvisaari; Outi Mantere; Jaakko Keinänen; Teemu Mäntylä; Eva Rikandi; Maija Lindgren; Tuula Kieseppä; Tuukka T Raij
Journal:  Front Psychiatry       Date:  2018-11-13       Impact factor: 4.157

6.  Exposure to common infections and risk of suicide and self-harm: a longitudinal general population study.

Authors:  Maija Lindgren; Minna Holm; Niina Markkula; Tommi Härkänen; Faith Dickerson; Robert H Yolken; Jaana Suvisaari
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2020-03-26       Impact factor: 5.270

7.  Network Association of Biochemical and Inflammatory Abnormalities With Psychiatric Symptoms in First-Episode Schizophrenia Patients.

Authors:  Junwei Yan; Yuanyuan Chen; Peijun Ju; Jianliang Gao; Loufeng Zhang; Jingwei Li; Keming Wang; Jie Zhang; Chao Li; Qingrong Xia; Cuizhen Zhu; Xulai Zhang
Journal:  Front Psychiatry       Date:  2022-02-22       Impact factor: 4.157

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.